What is HC Wainwright’s Estimate for GPCR Q1 Earnings?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Structure Therapeutics in a research report issued on Thursday, November 12th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings of ($0.58) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($2.05) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q2 2027 earnings at ($0.59) EPS.

Several other research analysts have also weighed in on the company. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen lowered Structure Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 3rd. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a report on Friday, August 7th. Citizens Jmp reissued a “market outperform” rating and issued a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Finally, Weiss Ratings upgraded Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $110.91.

Structure Therapeutics Trading Down 5.3%

GPCR opened at $19.84 on Friday. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -15.38 and a beta of -1.12. Structure Therapeutics has a 1 year low of $18.70 and a 1 year high of $94.90. The stock has a fifty day moving average price of $28.43 and a 200 day moving average price of $46.40.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15).

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds have recently bought and sold shares of GPCR. Squarepoint Ops LLC raised its holdings in Structure Therapeutics by 454.5% during the second quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after buying an additional 102,929 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Structure Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after acquiring an additional 119,146 shares in the last quarter. Orbimed Advisors LLC boosted its stake in shares of Structure Therapeutics by 27.0% during the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after acquiring an additional 313,600 shares in the last quarter. Handelsbanken Fonder AB bought a new stake in shares of Structure Therapeutics during the 2nd quarter worth about $1,041,000. Finally, SEB Asset Management AB acquired a new position in shares of Structure Therapeutics during the 1st quarter valued at about $11,811,000. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.